Glucorine Label Guide: 450 mg Myo-Inositol in a Seven-Active Formula
TL;DR:
- Start with the verified Glucorine label, daily serving and warning language.
- Use the three cited scientific sources as context; do not convert them into a finished-product medical claim.
- Keep suitability conditional on the complete formula, current label and individual professional guidance.
Glucorine's verified label lists myo-inositol at 450 mg in the recommended daily serving of two capsules. That number is useful, but it is only one part of the label. The same serving also declares alpha-lipoic acid, fenugreek, zinc, niacin, chromium and black pepper, creating a seven-active formula rather than a stand-alone myo-inositol product.
This guide is designed for label comparison, not product efficacy. It separates composition facts from authorized nutrient claims and ingredient research. It also reflects current commerce status: at the 1 September 2026 editorial check, the product was ACTIVE in Shopify, but the mapped variant had zero inventory and was unavailable on the storefront. This article is not a purchase invitation and makes no stock promise.
Table of Contents
- Start With the Two-Capsule Serving
- Read 450 mg in the Full Formula
- Separate Label Facts From Health Claims
- Interpret Authorized Wording Carefully
- Use Human Research With Transfer Limits
- Check Warnings, Allergens and Availability
- A Practical Buyer-Label Workflow
Key Takeaways
| Question | What the verified label establishes | What it does not establish |
|---|---|---|
| Serving | Two capsules per day | An individualized amount for every person |
| Myo-inositol | 450 mg per daily serving | A stand-alone intervention or research match |
| Formula | Seven declared active entries | That one ingredient explains the finished formula |
| Nutrient claims | Qualified EU wording for niacin, chromium and zinc | A medical statement or guaranteed personal result |
| Availability | The catalog item was ACTIVE at the check | Purchasability; the mapped variant was unavailable |
Start With the Two-Capsule Serving
The current Glucorine product information should be read together with the primary regulatory label. The label's reporting unit is the complete two-capsule daily serving. The declared amounts should not be presented as single-capsule values unless the label supplies that breakdown.
For two capsules, the panel lists 450 mg myo-inositol, 400 mg alpha-lipoic acid, 150 mg fenugreek seed extract, 10 mg zinc, 16 mg niacin, 25 micrograms chromium and 5 mg black pepper fruit extract. These are composition facts. They do not prove absorption, effectiveness, suitability or a finished-product outcome.
| Declared entry | Amount per two capsules | Best label-reading question |
|---|---|---|
| Myo-inositol | 450 mg | Did a cited study use this amount and this combination? |
| Alpha-lipoic acid | 400 mg | Is the studied material and schedule comparable? |
| Fenugreek | 150 mg | Does a source specify the extract rather than only the plant name? |
| Zinc | 10 mg | Which qualified authorized wording applies? |
| Niacin | 16 mg | Is the sentence a nutrient claim rather than a product promise? |
| Chromium | 25 micrograms | Does the wording retain the word normal? |
| Black pepper | 5 mg | Is it treated as a label entry rather than absorption proof? |
Read 450 mg in the Full Formula
The phrase "450 mg myo-inositol" can look like the product's whole identity during a quick comparison. The complete label gives a different picture. Myo-inositol is the largest declared entry by weight, but the serving contains six other active entries. A buyer guide should retain that architecture instead of turning a multi-ingredient formula into a single-ingredient comparison.
The number also needs its unit and serving. "450 mg" without "per two-capsule daily serving" is incomplete. It should not be divided, multiplied or described as a research-matched amount unless a source uses the same material, amount, schedule and conditions. A shared ingredient name begins a comparison; it does not make two interventions interchangeable.
The presence of 5 mg black pepper likewise cannot become a guaranteed bioavailability statement. The label confirms an ingredient and amount. Demonstrating an effect on this finished formula would require product-specific evidence that the panel does not supply.
Separate Label Facts From Health Claims
The EU Food Supplements Directive requires supplement labeling to identify the recommended daily portion and carry defined warning information. It also prevents supplement labeling from attributing disease prevention, treatment or curative properties. Composition, permitted health wording and clinical evidence are different layers.
That distinction matters here. "Myo-inositol 450 mg" is a label fact. An authorized nutrient sentence applies only to the nutrient named and only when the applicable conditions are satisfied. A statement that Glucorine produces a clinical result would be a different proposition and is not established by either the amount line or permitted wording.
The safest reading sequence is composition first, authorized wording second and research context third. Reversing that order allows a study headline to overshadow the actual serving, formula and warnings.
Interpret Authorized Wording Carefully
The verified label gives niacin at 16 mg, zinc at 10 mg and chromium at 25 micrograms, reported as 100%, 100% and 63% of their respective nutrient reference values. The consolidated EU permitted-claims list is the controlling source for exact wording and conditions rather than a paraphrase from memory.
For niacin, permitted wording includes that it contributes to normal energy-yielding metabolism and to the reduction of tiredness and fatigue. "Contributes to" and "normal" are essential limits. The wording does not mean that the product supplies energy directly, addresses a medical cause of fatigue or guarantees that an individual will feel different.
For chromium, permitted wording includes contribution to normal macronutrient metabolism and to the maintenance of normal blood glucose levels. It must not be rewritten as a therapeutic statement or a substitute for professional care. A normal-function nutrient claim is not a disease claim.
Zinc has permitted wording for several normal physiological functions, including normal carbohydrate metabolism. That does not turn a multi-ingredient supplement into an intervention, and it does not establish that zinc, myo-inositol or any other entry determines the formula's overall effect.
Use Human Research With Transfer Limits
The first primary human source, PMID 20811299, randomized 80 postmenopausal women with metabolic syndrome to diet plus myo-inositol or diet plus placebo for six months. Its myo-inositol protocol was 2 g twice daily, or 4 g per day. That is about 8.9 times the 450 mg label amount, in a specific population with a dietary co-intervention. Reported changes belong to that protocol; they are not a result for Glucorine.
The second source, PMID 36557221, was an open-label randomized six-month comparison of 4 g daily myo-inositol and 2 g daily metformin in women with polycystic ovary syndrome. Forty-five participants were randomized and 28 completed the study. HOMA-IR did not change and the metabolic outcomes did not favor myo-inositol. The open-label design, attrition, population and 8.9-fold dose distance all prevent transfer to this product.
The third source, PMID 27807448, was a small uncontrolled pilot in 20 adults with type 2 diabetes who continued medication. It used 550 mg myo-inositol plus 13.8 mg D-chiro-inositol and folate twice daily for three months, or 1.1 g myo-inositol per day. Changes from baseline cannot isolate myo-inositol from the combination, medication, diet, activity or time. Even its closer 2.4-fold amount is not a study of 450 mg or the seven-active formula.
These research amounts are comparisons, not capsule targets. They must never be converted into advice to multiply the label serving. The studies are most useful as a transfer checklist: identity, amount, schedule, population, co-interventions, endpoint and design. For all three, the answer to "Did it test Glucorine?" is no.
Check Warnings, Allergens and Availability
The primary label reserves the product for adults and advises against use during pregnancy or breastfeeding. It says the formula contains plant extracts and advises consultation with a doctor or pharmacist when medication is used, especially medication affecting blood glucose. The recommended daily dose should not be exceeded, and a supplement does not replace a varied, balanced diet and healthy lifestyle.
No named allergen statement was identified in the verified material. That absence does not establish that the product is allergen-free or appropriate for every allergy. Anyone needing allergen certainty should rely on the current physical label and qualified advice rather than an inference from silence.
Availability is a separate mutable fact. At the editorial check, Shopify classified the product as ACTIVE and the public page returned HTTP 200, while the mapped variant showed zero inventory, an inventory policy of deny and storefront availability false. ACTIVE described catalog status, not purchasability. This guide does not tell readers that the variant can currently be ordered.
A Practical Buyer-Label Workflow
- Confirm the serving: two capsules per day.
- Copy all seven entries: do not isolate 450 mg myo-inositol from the formula.
- Keep units exact: chromium is expressed in micrograms; the other listed amounts use milligrams.
- Separate evidence layers: label facts, permitted nutrient wording and ingredient research are not interchangeable.
- Check transfer: compare material, amount, schedule, population, co-interventions and endpoint.
- Preserve wording: retain "contributes to" and "normal"; do not create medical promises.
- Review suitability: adult-use, pregnancy and medication warnings remain part of the decision.
- Verify current status: ACTIVE catalog status does not override storefront unavailability.
The defensible conclusion is narrow. Glucorine declares 450 mg myo-inositol within a seven-active, two-capsule daily formula. Niacin, chromium and zinc can be discussed with exact permitted nutrient wording when all conditions are met, but those claims do not prove a clinical result from the product. The cited papers provide context for disciplined comparison; none tests Glucorine, and none removes the need to read the complete label, warnings and current availability.
Frequently Asked Questions
How much myo-inositol does the Glucorine label declare?
The verified label declares 450 mg per recommended daily serving of two capsules. That is a composition fact, not a personal dose recommendation or proof of an outcome.
Is Glucorine a stand-alone myo-inositol supplement?
No. The two-capsule serving lists seven active entries: myo-inositol, alpha-lipoic acid, fenugreek, zinc, niacin, chromium and black pepper.
Do authorized niacin, chromium and zinc claims prove a Glucorine result?
No. Authorized wording describes contributions to normal functions when its conditions are met. It does not establish a medical benefit or guaranteed result from the finished product.
Did the cited human studies test Glucorine?
No. They used different myo-inositol amounts, populations, schedules and co-interventions. None tested the current seven-active Glucorine formula.
Is Glucorine currently available to purchase?
At the 1 September 2026 check, Shopify listed the product as ACTIVE, but the mapped variant had zero inventory and storefront availability was false. This guide makes no purchase or stock promise.
Recommended
- Glucorine: ALA, chromium and piperine pathway guide
- Five criteria for reading a metabolic-support supplement label
- Metabolic flexibility: an evidence-context guide
- Review the current Glucorine product information
Our research and formulas have been recognized by leading media outlets such as Marie Claire.
Scientific References
- Giordano et al. (2011): randomized placebo-controlled six-month myo-inositol study in 80 postmenopausal women with metabolic syndrome
- Neal et al. (2023): open-label randomized six-month myo-inositol versus metformin study in women with polycystic ovary syndrome
- Pintaudi et al. (2016): small uncontrolled three-month myo- and D-chiro-inositol combination pilot in adults with type 2 diabetes
These statements have not been evaluated by the Food and Drug Administration. BioEssentials products are food supplements intended to support general wellness and daily nutritional needs. They are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before starting any new supplement if you are pregnant, breastfeeding, taking medication, or managing a health condition.
